EICHORCondition: Advanced Solid Tumor · Sponsor: Xilio Development, Inc.
This is a first-in-human, Phase 1/2, multicenter, open-label study designed to evaluate the safety and tolerability of vilastobart (XTX101) as monotherapy and vilastobart (XTX101) and atezolizumab combination therapy in patients with advanced solid tumors.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Mayo Clinic Hospital | Phoenix, Arizona, United States | — |
| City of Hope | Duarte, California, United States | — |
| California Cancer Associates for Research and Excellence, cCARE | Encinitas, California, United States | — |
| City of Hope-Lennar | Irvine, California, United States | — |
| USC/Norris Comprehensive Cancer Center | Los Angeles, California, United States | — |
| California Cancer Associates for Research and Excellence, cCARE | San Marcos, California, United States | — |
| UCLA Hematology/Oncology- Santa Monica | Santa Monica, California, United States | — |
| City of Hope-Upland | Upland, California, United States | — |
| Mayo Clinic Hospital | Jacksonville, Florida, United States | — |
| Sarah Cannon Research Institute at Florida Cancer Specialists | Orlando, Florida, United States | — |
| Massachusetts General Hospital | Boston, Massachusetts, United States | — |
| Mayo Clinic Hospital | Rochester, Minnesota, United States | — |
+ 7 more locations — full list on the registry record.
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04896697